Deutetrabenazine Production Cost Reports

The report provides a detailed analysis essential for establishing a deutetrabenazine production plant. It encompasses all critical aspects necessary for deutetrabenazine production, including the cost of deutetrabenazine production, deutetrabenazine plant cost, deutetrabenazine production costs, and the overall deutetrabenazine production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a deutetrabenazine production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Deutetrabenazine is a prescription medicine used in the pharmaceutical and healthcare industry for the treatment of movement-related neurological disorders. It is mainly utilised as a drug for managing involuntary movements associated with Huntington’s disease and tardive dyskinesia. It works by regulating certain chemicals in the brain that control muscle movement, helping to reduce jerking, twitching, and uncontrolled motions.

It is commonly prescribed to manage chorea, which is the involuntary, jerky movements seen in people with Huntington’s disease. It supports long-term symptom management and helps patients maintain better control over daily activities. It is also used to treat tardive dyskinesia, which is a condition where people experience repetitive, uncontrolled movements, usually caused by long-term use of certain psychiatric medications.

The market for deutetrabenazine is mainly driven by its application as an oral drug in the treatment of chronic neurological conditions, which promotes its demand in the medical and pharmaceutical industries. Its application as a medication in the treatment and management of tardive dyskinesia also strengthens its demand in the pharmaceutical industry.

Its usage in the treatment of Huntington's disease (HD), which is characterised by cognitive decline, motor dysfunction, and neuropsychiatric disturbances, further boosts its demand in the medical and healthcare sectors. Its demand as a drug for the treatment of neurodegenerative diseases and alleviate the motor symptoms of HD further supports its market expansion. Additionally, industrial deutetrabenazine procurement is shaped by factors such as the complexity of the synthesis process, availability and cost of raw materials, patent exclusivity, and regulatory approvals. Furthermore, consistent supply chains, production standards, and adherence to safety protocols also impact its procurement and global market trends.

Raw Material for Deutetrabenazine Production

According to the deutetrabenazine production plant project report, the major raw materials for deutetrabenazine production include Dihydroxy isoquinoline compound, (2-acetyl-4-methyl-pentyl)-trimethyl-ammonium iodide, and Deuterated Methanol.

Production Process of Deutetrabenazine

The extensive deutetrabenazine production cost report consists of the following industrial production process:

1. Production via Chemical Synthesis: The production process of deutetrabenazine begins with the reaction of a dihydroxy isoquinoline compound with a quaternary ammonium salt, specifically (2-acetyl-4-methyl-pentyl)-trimethyl-ammonium iodide, to form a dihydroxy benzoquinoline intermediate. This is a major step which constructs the core structure needed for the active scaffold. The resulting intermediate is then further processed and converted through a series of reactions into tetrabenazine. Further, the resulting compound is reacted with deuterated methanol in the presence of triphenylphosphine and DIAD, which results in the formation of deutetrabenazine as the final product.

Deutetrabenazine is a vesicular monoamine transporter 2 inhibitor used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia in adults. It appears as a white to slightly yellow crystalline powder that is sparingly soluble in water and soluble in ethanol. The molecular formula of the compound is C19H27NO3, and its molecular mass is 323.5 g/mol. The compound is an isotopic isomer of tetrabenazine in which six hydrogen atoms on the two methoxy groups are replaced by deuterium atoms. The most common adverse effects include somnolence, diarrhoea, dry mouth, fatigue, nasopharyngitis, and insomnia. Serious adverse effects include depression, suicidal thoughts and behavior particularly in patients with Huntington's disease, neuroleptic malignant syndrome, QT prolongation, hypotension, sedation, and Parkinsonism. It is contraindicated in patients with depression or suicidal ideation, in those taking monoamine oxidase inhibitors, reserpine, or related VMAT2 inhibitors, and in patients with hepatic impairment.